Welldoc Works with Lilly to Launch a New Personalized Health & Medicine Platform for Those Prescribed Lilly's Incretin Therapies
Lilly and Welldoc aim to build a more seamless patient experience through educational resources and targeted support. The Lilly Health app will provide features to help patients with their cardiometabolic health goals and weight, such as medication logging, reminders, device connectivity and health data tracking.
"We are incredibly proud to expand our impactful work with Lilly. Welldoc's robust and AI-powered digital health platform is uniquely equipped to be a powerful foundation for the Lilly Health app,' said Kevin McRaith, President and CEO of Welldoc. 'Our proven ability to integrate complex data, deliver personalized insights and support individuals across multiple cardiometabolic conditions positions us as the ideal technology partner for Lilly's ambitious vision. We are confident that our scalable and secure platform will enable Lilly Health to deliver a truly transformative and connected experience for patients.'
The Lilly Health app is built upon Welldoc's well-established digital cardiometabolic platform, which provides individuals with extensive device and data connectivity, in-app nutrition and exercise resources, and comprehensive trends and insights to help individuals manage complex cardiometabolic conditions with their providers and optimize their overall health over time.
About Welldoc
Welldoc ®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc's comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs.
Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 50+ patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, The Wall Street Journal and The Economist. The company has been named the 'Best Overall Digital Health Company' by MedTech Breakthrough for the past two years and was selected as a winner of the 2025 AI Excellence Awards by Business Intelligence Group, 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit www.welldoc.com. Follow us on LinkedIn and X.
*Lilly Health™ Personalized Health & Medicine Platform
Lilly Health Personalized Health & Medicine Platform is intended for use as a health management aid for adult patients 18 years or older who have been prescribed Zepbound® (tirzepatide) or Mounjaro® (tirzepatide).
Lilly Health provides Zepbound and Mounjaro users with medication reminders, medication dose logging, and health data logging.
Lilly Health is not intended to provide treatment decisions or replace the care and advice of a licensed Health Care Provider (HCP). All medical analysis and treatment plans should be performed by a licensed HCP.
** Zepbound® (tirzepatide)
Zepbound is an injectable prescription medicine that may help adults with:
obesity, or some adults with overweight who has have weight-related medical problems to lose excess body weight and keep the weight off
moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.
It should be used with a reduced-calorie diet and increased physical activity.
Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.
See www.zepbound.lilly.com for full indications of use.
**Mounjaro® (tirzepatide)
Mounjaro is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus.
It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age.
See www.mounjaro.lilly.com for full indications of use.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre
LONDON--(BUSINESS WIRE)--This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This state-of-the-art facility will enhance Haleon's science capabilities, accelerate innovation, and serve as a centre of excellence for global oral health research. The groundbreaking ceremony, attended by UK Minister Baroness Jones, marks an important step in Haleon's ambition to reach one billion more consumers by 2030, by strengthening its oral health R&D capabilities to put health in more hands globally. Set to become the R&D epicentre for Haleon's oral health portfolio, the centre will be a dynamic hub for pioneering research, product innovation, commercial and supply chain excellence, and cross-functional collaboration. Equipped with the latest technology and global expertise, the centre will feature a cutting-edge digital immersive room designed to unlock value at pace through real-time collaboration with Haleon's manufacturing site in Levice. At the heart of the building, the atrium will create a vibrant hub for teamwork and co-creation, bringing leading expertise together to develop solutions that address unmet oral health needs for consumers around the world. Designed with sustainability at its core, the site has recently achieved a BREEAM® Outstanding rating, recognising its exceptional commitment to sustainability at Phase 1 in the design stage. Franck Riot, Chief R&D Officer, Haleon, said:" We are excited to break ground on our Global Oral Health Innovation Centre - a major investment reflecting our commitment to advancing science and innovation. This powerhouse for oral health research will strengthen Haleon's R&D capabilities and accelerate the development of cutting-edge solutions to meet the evolving oral health needs of consumers around the world. ' Chancellor of the Exchequer, Rachel Reeves MP, said: 'This exciting milestone is another demonstration of the strength of the UK life sciences sector, a key pillar to our Industrial Strategy. Under this government Britain is open for business, and through our Plan for Change we're delivering more investment, more jobs and more money in people's pockets.' UK Minister for Technology, Baroness Jones, said: 'Haleon is breaking ground on a new centre that will place the UK at the forefront of innovation to improve everyone's oral health - which we know is important to our wider health, and to children's development. This centre, and the substantial investment behind it, is proof that the UK's world-leading life sciences sector is the place to be to grow businesses and work on fresh ideas to transform healthcare. Leveraging these strengths will lead to the long-term economic growth that will help us deliver on our Plan for Change.' Jayant Singh, Global Category Lead, Oral Health, Haleon, said:" With oral diseases affecting nearly half the world's population, this marks an exciting step forward in our mission to put health in more hands for millions across the world. This centre will play a key role in harnessing the full potential of science and innovation across our oral health portfolio. ' About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
Associated Press
5 hours ago
- Associated Press
MIT Alumni Unveil EON.HEALTH, an AI Longevity Platform Putting People Back in Charge of Their Health
AI-powered platform, now available for all, turns personal health data into actionable insights to help users live longer, healthier lives. 'Normal isn't biology, it's a shifting social construct. At EON, we empower people to understand their data and define baseline, make health decisions based on their trajectory, not outdated averages.'— Ki-youn Jung, Co-founder and CEO, BOSTON, MA, UNITED STATES, July 4, 2025 / / -- a groundbreaking longevity technology platform, officially launches today on Independence Day, symbolizing a new era of health independence for Americans. The AI-powered platform analyzes personal health, fitness, diet, and mindfulness data to provide scientifically-backed insights and personalized recommendations designed to extend healthspan and optimize quality of life. Founded by MIT alumni Ki-youn Jung and Dr. Abhishek Singh, addresses the growing demand for personalized healthcare solutions by transforming raw health data into actionable intelligence. The platform's unique approach combines individual data analysis with collective learning from peer experiences, enabling users to discover their personal 'baseline' and optimize their longevity journey across six interconnected health pillars. 'Just as America declared independence 249 years ago, we're empowering individuals to declare independence from one-size-fits-all health approaches,' said Ki-youn Jung, Co-founder and CEO of 'Our platform doesn't just track data, it reveals patterns unique to each person and provides a roadmap for their optimal health journey. True health independence means understanding your body's individual needs and having the tools to act on that knowledge.' Beyond Tracking: The Science of Personalized Longevity Unlike traditional health apps that focus on single metrics, takes a holistic approach through six scientifically-validated pillars: Recovery, Nutrition, Movement, Connection, Cognition, and Aesthetics. The platform's AI engine analyzes patterns across these interconnected areas to identify optimization opportunities specific to each user's biological and lifestyle profile. 'Most health platforms tell you what happened, we tell you what to do next,' explained Dr. Abhishek Singh, Co-founder and Chief Technology Officer. 'Our decentralized AI approach for precision medicine means recommendations become more accurate as users share anonymized insights, creating a collective intelligence that benefits everyone while protecting individual privacy.' The platform's 'Hive' feature leverages collective learning, allowing users to learn from similar profiles and successful optimization strategies within the community, while maintaining complete data privacy and user control. Founders' Vision: Democratizing Longevity Science Ki-youn Jung brings a unique perspective as a Korean entrepreneur who previously developed AI+IoT platform strategies for $20B global businesses and designed semiconductor processors before earning her MBA from MIT Sloan School of Management. Her corporate intrapreneur background provides crucial insight into scaling complex technology platforms. Dr. Abhishek Singh, an MIT PhD scientist and engineer, focuses his research on decentralized AI for precision medicine. His extensive experience in developing novel ideas and building large-scale systems forms the technical foundation for sophisticated AI capabilities. 'We're committed to revolutionizing healthy living through cutting-edge technology that enables individuals to take control of their health and enhance their longevity,' said Jung. 'The longevity tech industry is at an inflection point, people want personalized solutions backed by science, not generic advice.' Timing Aligns with National Health Technology Push launch coincides with renewed federal interest in personal health technology. The platform directly addresses the growing quantified-self movement, targeting the 25-55 age demographic of longevity enthusiasts and wearable device users who seek deeper insights from their health data. 'The future of healthcare is personal, predictive, and preventive,' added Dr. Singh. 'We're not just building another health app, we're creating an AI companion that evolves with users and helps them achieve maximum functionality at every age.' Cagla Tok +1 617-901-9436 email us here Visit us on social media: LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Business Wire
7 hours ago
- Business Wire
Form 8.3 - Life Science REIT plc
BOSTON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the 'Code') 1. KEY INFORMATION (a) Full name of discloser: Weiss Asset Management LP (Investment Manager of Brookdale International Partners, L.P. and Brookdale Global Opportunity Fund) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Life Science REIT plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 3 July 2025 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state 'N/A' N/A Expand 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 1p ordinary – 350,000,000 (ISIN: GB00BP5X4Q29) Interests Short Positions Number % Number % (1) Relevant securities owned and/or controlled: (2) Cash-settled derivatives: 5,080,638 1.45 (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 5,080,638 1.45 Expand All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: N/A Details, including nature of the rights concerned and relevant percentages: N/A Expand 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/Sale Number of securities Price per unit N/A N/A N/A N/A Expand (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. Opening/Closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit 1p ordinary CFD Increasing a long position 100,000 GBP 0.4400 1p ordinary CFD Increasing a long position 8,111 GBP 0.4390 Expand (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit N/A N/A N/A N/A N/A N/A N/A N/A Expand (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit N/A N/A N/A N/A N/A Expand (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) N/A N/A N/A N/A Expand 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state 'none' None Expand (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state 'none' None Expand (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? No Expand Date of disclosure: 4 July 2025 Contact name: Mary Merrigan Telephone number: +1 617 778 7775 Expand Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel's website at
